Precision BioSciencesDTIL
About: Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Employees: 108
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 9
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
10% more funds holding
Funds holding: 51 [Q3] → 56 (+5) [Q4]
4.61% more ownership
Funds ownership: 45.97% [Q3] → 50.58% (+4.61%) [Q4]
51% less capital invested
Capital invested by funds: $29.8M [Q3] → $14.7M (-$15.1M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Patrick Trucchio 20% 1-year accuracy 10 / 51 met price target | 1,179%upside $60 | Buy Reiterated | 28 Mar 2025 |
BMO Capital Kostas Biliouris 6% 1-year accuracy 1 / 17 met price target | 625%upside $34 | Outperform Upgraded | 10 Jan 2025 |
Financial journalist opinion
Based on 8 articles about DTIL published over the past 30 days









